The company trades in cut and polished diamonds and precious metals, primarily sourcing and selling to jewelry manufacturers and retailers.
The company operates in a highly fragmented commodity trading market with no evidence of brand power or cost advantages, as reflected by persistent negative returns and high volatility in margins. The rise of lab-grown diamonds is actively eroding the market for their core natural diamond product.
Capital is primarily tied up in stagnant inventory and trade receivables that show poor turnover. Management has failed to generate positive returns on equity over the long term, and the balance sheet is heavily reliant on unsecured loans from the promoter to stay afloat.
Five years out, the company has likely collapsed under the weight of its own insolvency. The massive pile of aged trade receivables, which were already three years overdue in 2024, finally proved uncollectible, forcing a total write-down of the balance sheet. Without the ability to convert inventory or receivables into cash, and with the promoter's unsecured loans reaching their limit, the business could no longer service its extreme debt load. The shift toward lab-grown diamonds rendered their stagnant natural diamond inventory obsolete, leaving the company as a hollow shell with more liabilities than assets.
RichFakir rates Sunraj Diamond Exports Ltd's business quality as poor — 5/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Sunraj Diamond Exports Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Sunraj Diamond Exports Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Sunraj Diamond Exports Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →